Continuous Subcutaneous Delivery of Exenatide via ITCA 650 Leads to Sustained Glycemic Control

Significant changes in HbA1c, body weight, and FPG attained with ITCA 650 were maintained to 48 weeks. The incidence of AEs was lower in the 24-week extension than in the initial 24-week treatment phase (Diabetes and Its Complications)